The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Antonio Cigliola
No Relationships to Disclose
 
Brigida Anna Maiorano
No Relationships to Disclose
 
Valentina Tateo
No Relationships to Disclose
 
Chiara Mercinelli
No Relationships to Disclose
 
Michela Piacentini
No Relationships to Disclose
 
Alessandro Bertini
No Relationships to Disclose
 
Marco Mariani
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Eisai
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Research Funding - Adicet Bio (Inst); Adicet Bio (Inst); ArsenalBio (Inst); crispr therapeutics (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Miyarisan pharmaceutical (Inst); Osel (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Shilpa Gupta
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; Johnson & Johnson/Janssen; Merck; Natera; Novartis; Pfizer
Research Funding - Acrivon Therapeutics (Inst); Amgen (Inst); Bristol Myers Squibb Foundation (Inst); Convergent Therapeutics (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Tyra Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Astellas Pharma; Merck; Pfizer
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Foundation Medicine; Gilead Sciences; Janssen; Lilly; Merck; Pfizer; Replimune; Roche; Strata Oncology; Tyra Biosciences; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Ashish Kamat
Leadership - American Urological Association; International Bladder Cancer Group (IBCG); World Bladder Cancer Patient Coalition
Consulting or Advisory Role - Aspira Women's Health (I); Astellas Pharma; Atonco Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Cystotech; Eisai; enGene; Ferring; Genentech; Imagin Medical; ImmunityBio; Imvax; Incyte; Janssen; Medac; Merck; Nonagen Bioscience; Pfizer; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; Urogen pharma; US Biotest; Valar Labs; Vivet Therapeutics
Research Funding - Arquer Diagnostics (Inst); enGene (Inst); FKD Therapies (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Photocure (Inst); Seagen (Inst); SWOG (Inst)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; Journal of Urology; UroToday
 
Philippe Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN; President of Global Society of Rare GU Tumors; Société Internationale d’Urologie Journal
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Alberto Briganti
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Ferring; Hauora; Janssen-Cilag; MDxHealth; OPKO Health; Pfizer
Speakers' Bureau - Astellas Pharma
Research Funding - Merck Sharp & Dohme; Sandoz-Novartis
 
Francesco Montorsi
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Johnson & Johnson/Janssen; Merck Serono; Merck Sharp & Dohme; Peerview; PeerVoice; Samsung Bioepis; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Janssen; Merck Sharp & Dohme